Q2 EPS Estimates for Bausch + Lomb Lifted by HC Wainwright

Key Points

• HC Wainwright raised its Q2 2026 EPS estimate for Bausch + Lomb to $0.21 (from $0.18), kept a Buy rating and a $20 price target, and provided EPS forecasts through Q4 2027.
• Bausch + Lomb recently reported $0.08 EPS (versus a $0.06 consensus) and $1.24 billion in revenue (versus $1.22 billion), with revenue up 9.4% year-over-year despite a negative net margin of 4.21%.
• Insider buying occurred in March, with CEO Brent Saunders and EVP Robert D. Bailey each purchasing roughly 14,600–14,700 shares, increasing insider ownership and signaling management confidence.

Bausch + Lomb Corporation (NYSE:BLCO - Free Report) - Equities researchers at HC Wainwright increased their Q2 2026 earnings estimates for shares of Bausch + Lomb in a research note issued on Monday, May 4th. HC Wainwright analyst Y. Chen now anticipates that the company will earn $0.21 per share for the quarter, up from their prior forecast of $0.18. HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Bausch + Lomb's current full-year earnings is $0.79 per share. HC Wainwright also issued estimates for Bausch + Lomb's Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.34 EPS, Q2 2027 earnings at $0.22 EPS, Q3 2027 earnings at $0.23 EPS and Q4 2027 earnings at $0.41 EPS.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its earnings results on Wednesday, April 29th. The company reported $0.08 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.02. The business had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.22 billion. Bausch + Lomb had a negative net margin of 4.21% and a positive return on equity of 3.60%. The company's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.07) EPS.

Other equities research analysts have also recently issued research reports about the stock. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $19.00 price target on shares of Bausch + Lomb in a research report on Friday, January 9th. Stifel Nicolaus set a $16.00 price target on shares of Bausch + Lomb in a research report on Thursday, February 19th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Bausch + Lomb in a research report on Monday, April 20th. Royal Bank Of Canada upped their price target on shares of Bausch + Lomb from $19.00 to $21.00 and gave the stock an "outperform" rating in a research report on Tuesday, January 27th. Finally, Barclays upped their price target on shares of Bausch + Lomb from $17.00 to $20.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 19th. Four research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Bausch + Lomb presently has a consensus rating of "Hold" and a consensus target price of $18.08.

Bausch + Lomb Price Performance

Shares of BLCO stock opened at $16.31 on Tuesday. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.53 and a quick ratio of 0.99. The company has a market capitalization of $5.81 billion, a P/E ratio of -26.30, a P/E/G ratio of 0.52 and a beta of 0.59. The company's 50-day simple moving average is $16.65 and its two-hundred day simple moving average is $16.53. Bausch + Lomb has a one year low of $10.83 and a one year high of $18.92.

Insider Transactions at Bausch + Lomb

In other news, CEO Brent L. Saunders bought 14,700 shares of the firm's stock in a transaction that occurred on Friday, March 6th. The stock was bought at an average price of $17.14 per share, with a total value of $251,958.00. Following the completion of the transaction, the chief executive officer directly owned 966,575 shares of the company's stock, valued at approximately $16,567,095.50. The trade was a 1.54% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP A Robert D. Bailey bought 14,600 shares of the firm's stock in a transaction that occurred on Friday, March 6th. The shares were purchased at an average cost of $17.15 per share, with a total value of $250,390.00. Following the transaction, the executive vice president directly owned 231,890 shares of the company's stock, valued at $3,976,913.50. The trade was a 6.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders acquired 33,300 shares of company stock valued at $570,868. Company insiders own 1.45% of the company's stock.

Institutional Investors Weigh In On Bausch + Lomb

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tudor Investment Corp ET AL purchased a new stake in Bausch + Lomb during the third quarter valued at approximately $2,249,000. Goldentree Asset Management LP lifted its position in Bausch + Lomb by 3.0% during the third quarter. Goldentree Asset Management LP now owns 2,660,508 shares of the company's stock valued at $40,002,000 after acquiring an additional 77,323 shares during the last quarter. Compass Rose Asset Management LP lifted its position in Bausch + Lomb by 22.0% during the third quarter. Compass Rose Asset Management LP now owns 1,000,000 shares of the company's stock valued at $15,070,000 after acquiring an additional 180,000 shares during the last quarter. Oaktree Capital Management LP lifted its position in Bausch + Lomb by 28.7% during the third quarter. Oaktree Capital Management LP now owns 3,245,439 shares of the company's stock valued at $48,909,000 after acquiring an additional 724,194 shares during the last quarter. Finally, Handelsbanken Fonder AB lifted its position in Bausch + Lomb by 34.8% during the fourth quarter. Handelsbanken Fonder AB now owns 20,900 shares of the company's stock valued at $357,000 after acquiring an additional 5,400 shares during the last quarter. Hedge funds and other institutional investors own 11.07% of the company's stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.